Contact
searchSearch
HMP Global
Login

CAR-T Therapies Resource Center

Featured

Conference Coverage
Hospital Costs and Health Care Resource Utilization for Chimeric Antigen T-Cell Therapy and Stem Cell Transplant in Patients with Large B-Cell Lymphoma in the United States
12/12/2022
Katie Herman
At the 64th ASH Annual Meeting and Exposition, Gunjan L Shah, MD, described and compared hospital costs and health care resource utilization of chimeric antigen T-cell therapy and stem cell transplant for the procedure, preprocedure, and...
At the 64th ASH Annual Meeting and Exposition, Gunjan L Shah, MD, described and compared hospital costs and health care resource utilization of chimeric antigen T-cell therapy and stem cell transplant for the procedure, preprocedure, and...
At the 64th ASH Annual Meeting...
12/12/2022
Journal of Clinical Pathways
Ajeet Gajra, MD, FACS
Videos
Barriers to CAR-T Therapy Utilization Among Community Hematologists/Oncologists in the US
01/19/2022
Ajeet Gajra, MD, FACS, discusses findings from a study analyzing the utilization of and barriers to CAR-T therapies by community hematologists/oncologists in the United States, discussing deterrents such as cost and lack of support.
Ajeet Gajra, MD, FACS, discusses findings from a study analyzing the utilization of and barriers to CAR-T therapies by community hematologists/oncologists in the United States, discussing deterrents such as cost and lack of support.
Ajeet Gajra, MD, FACS, discusses...
01/19/2022
Journal of Clinical Pathways
Irena Tan, MD, Stanford Cancer Institute
Videos
Impact of CAR-T Therapy on Quality of Life: Patient-Reported Outcomes vs Performance-Based Metrics
01/11/2022
Irena Tan, MD, discusses study findings comparing the impact of CAR-T therapy on patients’ quality of life, including patient-reported cognitive function and performance-based cognition.
Irena Tan, MD, discusses study findings comparing the impact of CAR-T therapy on patients’ quality of life, including patient-reported cognitive function and performance-based cognition.
Irena Tan, MD, discusses study...
01/11/2022
Journal of Clinical Pathways
Kristin Savill, Cardinal Health
Videos
Real-World Treatment With CAR-T Therapies Among Patients With DLBCL
01/11/2022
Kristin Savill, PhD, discusses real-world characteristics and treatment outcomes of patients with DLBCL treated with axicabtagene ciloleucel and tisangenlecleucel.
Kristin Savill, PhD, discusses real-world characteristics and treatment outcomes of patients with DLBCL treated with axicabtagene ciloleucel and tisangenlecleucel.
Kristin Savill, PhD, discusses...
01/11/2022
Journal of Clinical Pathways
Conference Coverage
Safety and Cost-Effectiveness of CAR-T Therapy in the Outpatient vs Inpatient Setting
12/08/2021
Janelle Bradley
Study findings presented at the 2021 ASH Annual Meeting demonstrate the feasibility and cost-effectiveness of outpatient administration of CAR-T therapy for patients with hematologic malignancies.
Study findings presented at the 2021 ASH Annual Meeting demonstrate the feasibility and cost-effectiveness of outpatient administration of CAR-T therapy for patients with hematologic malignancies.
Study findings presented at the...
12/08/2021
Journal of Clinical Pathways
News
HCRU and End-of-Life Outcomes Among Patients Receiving CAR-T Therapy
08/05/2021
Findings from a recent study indicate that intervention may be needed to optimize health care delivery and end-of-life care in patients with hematologic malignancies receiving CAR-T therapy.
Findings from a recent study indicate that intervention may be needed to optimize health care delivery and end-of-life care in patients with hematologic malignancies receiving CAR-T therapy.
Findings from a recent study...
08/05/2021
Journal of Clinical Pathways
CAR T-Cell Therapy: Current Practice and Future Solutions to Optimize Patient Access
CAR T-Cell Therapy: Current Practice and Future Solutions to Optimize Patient Access
03/15/2021
Praveen Ramakrishnan Geethakumari, MD; Ankit J. Kansagra, MD; Dheepthi Perumal Ramasamy, BS; Binod Dhakal, MD
Praveen Ramakrishnan Geethakumari, MD, and colleagues address clinical and financial challenges and provide solutions to optimize CAR-T cell therapy’s framework toward expanding access.
Praveen Ramakrishnan Geethakumari, MD, and colleagues address clinical and financial challenges and provide solutions to optimize CAR-T cell therapy’s framework toward expanding access.
Praveen Ramakrishnan...
03/15/2021
Journal of Clinical Pathways
Impact of CAR-T Therapy on HCRU and End-of-Life Outcomes in Hematologic Malignancies
Videos
Impact of CAR-T Therapy on HCRU and End-of-Life Outcomes in Hematologic Malignancies
12/20/2020
12/20/2020
Journal of Clinical Pathways
News
Real-World CAR-T Therapy Toxicity in Patients With DLBCL
11/11/2020
More studies exploring real-world experience and data are necessary and will help define and refine management of toxicities unique to CAR-T therapy.
More studies exploring real-world experience and data are necessary and will help define and refine management of toxicities unique to CAR-T therapy.
More studies exploring...
11/11/2020
Journal of Clinical Pathways
News
Tisagenlecleucel Yields Comparable Safety, Efficacy in Real-World and Trial Settings
11/11/2020
11/11/2020
Journal of Clinical Pathways
News
Multivariable Score Helps Predict Risk of Neurotoxicity After CAR-T Therapy
10/22/2020
10/22/2020
Journal of Clinical Pathways

Expert Insights

Ajeet Gajra, MD, FACS
Videos
Barriers to CAR-T Therapy Utilization Among Community Hematologists/Oncologists in the US
01/19/2022
Ajeet Gajra, MD, FACS, discusses findings from a study analyzing the utilization of and barriers to CAR-T therapies by community hematologists/oncologists in the United States, discussing deterrents such as cost and lack of support.
Ajeet Gajra, MD, FACS, discusses findings from a study analyzing the utilization of and barriers to CAR-T therapies by community hematologists/oncologists in the United States, discussing deterrents such as cost and lack of support.
Ajeet Gajra, MD, FACS, discusses...
01/19/2022
Journal of Clinical Pathways
Irena Tan, MD, Stanford Cancer Institute
Videos
Impact of CAR-T Therapy on Quality of Life: Patient-Reported Outcomes vs Performance-Based Metrics
01/11/2022
Irena Tan, MD, discusses study findings comparing the impact of CAR-T therapy on patients’ quality of life, including patient-reported cognitive function and performance-based cognition.
Irena Tan, MD, discusses study findings comparing the impact of CAR-T therapy on patients’ quality of life, including patient-reported cognitive function and performance-based cognition.
Irena Tan, MD, discusses study...
01/11/2022
Journal of Clinical Pathways
Kristin Savill, Cardinal Health
Videos
Real-World Treatment With CAR-T Therapies Among Patients With DLBCL
01/11/2022
Kristin Savill, PhD, discusses real-world characteristics and treatment outcomes of patients with DLBCL treated with axicabtagene ciloleucel and tisangenlecleucel.
Kristin Savill, PhD, discusses real-world characteristics and treatment outcomes of patients with DLBCL treated with axicabtagene ciloleucel and tisangenlecleucel.
Kristin Savill, PhD, discusses...
01/11/2022
Journal of Clinical Pathways
Editor Insights
CAR-T Reimbursement Levels Set by CMS, So Where Should Patients Be Treated?
04/19/2018
Winston Wong, PharmD
Will payers push for services to be provided on an outpatient basis, thus placing financial burden upon the patient, or will they allow the oncologist or facility to use their discretion as to where the infusion will take place?
Will payers push for services to be provided on an outpatient basis, thus placing financial burden upon the patient, or will they allow the oncologist or facility to use their discretion as to where the infusion will take place?
Will payers push for services to...
04/19/2018
Journal of Clinical Pathways
Guest Blog
Why Payers, Other Stakeholders Should Remain Optimistic About CAR-T Therapies
03/15/2018
Bruce A. Feinberg, DO; Chadi Nabhan, MD, MBA, FACP
Bruce A Feinberg, DO, and Chadi Nabhan, MD, MBA, FACP, contend that collaboration between payers and other stakeholders will help amend the concerns regarding newly approved CAR-T therapies.
Bruce A Feinberg, DO, and Chadi Nabhan, MD, MBA, FACP, contend that collaboration between payers and other stakeholders will help amend the concerns regarding newly approved CAR-T therapies.
Bruce A Feinberg, DO, and Chadi...
03/15/2018
Journal of Clinical Pathways
Editor Insights
The CAR-T Breakthrough: More Than Just Another Treatment Option
02/02/2018
Winston Wong, PharmD
While CAR T-cell therapies fill an unmet need in hematologic malignancies, they are not without risk and cost burdens, according to Winston Wong, PharmD.
While CAR T-cell therapies fill an unmet need in hematologic malignancies, they are not without risk and cost burdens, according to Winston Wong, PharmD.
While CAR T-cell therapies fill...
02/02/2018
Journal of Clinical Pathways
Headshots
Interview
Endometrial Cancer Risk Research Suggests Earlier Intervention Across Age Groups
09/17/2025
Mengmeng Du, ScD, MSc; Noah C. Peeri, PhD, MPH
In this interview, guest cancer epidemiologists share their findings on endometrial cancer risk in younger women, highlighting the powerful role of obesity and metabolic health, shared risk patterns across age groups, and the importance of...
In this interview, guest cancer epidemiologists share their findings on endometrial cancer risk in younger women, highlighting the powerful role of obesity and metabolic health, shared risk patterns across age groups, and the importance of...
In this interview, guest cancer...
09/17/2025
Journal of Clinical Pathways
BDHC thumbnail
Videos
Second Opinions in Oncology: Quality, Communication, and Patient Confidence
09/16/2025
John Hennessy, MBA; Michael Kolodziej, MD
In this episode of Breaking Down Health Care, John Hennessy and Dr Michael Kolodziej explore the many dimensions of second opinions in oncology—ranging from in-practice consultations to academic referrals, payer-sponsored programs, and...
In this episode of Breaking Down Health Care, John Hennessy and Dr Michael Kolodziej explore the many dimensions of second opinions in oncology—ranging from in-practice consultations to academic referrals, payer-sponsored programs, and...
In this episode of Breaking Down...
09/16/2025
Cancer Care Business Exchange
Golla Headshot
Videos
Driving Change: What the PCC Working Group Has Learned and What’s Next
09/10/2025
Vishnukamal Golla, MD, MPH
In this discussion, Dr Kamal Golla, vice president of clinical technology and performance at Evolent Health, shares how the Predictable Cost of Care model shifts the focus from drug acquisition costs to a comprehensive view of total care...
In this discussion, Dr Kamal Golla, vice president of clinical technology and performance at Evolent Health, shares how the Predictable Cost of Care model shifts the focus from drug acquisition costs to a comprehensive view of total care...
In this discussion, Dr Kamal...
09/10/2025
Journal of Clinical Pathways
Thawani Headshot
Videos
Progression-Free Survival in NSCLC: Clinical Utility, Limitations, and Evolving Standards
08/28/2025
Rajat Thawani, MD
Rajat Thawani, MD, shares key insights on balancing progression-free and overall survival, the expanding role of biomarker testing, and the promise of multi-omic data integration in reshaping NSCLC treatment.
Rajat Thawani, MD, shares key insights on balancing progression-free and overall survival, the expanding role of biomarker testing, and the promise of multi-omic data integration in reshaping NSCLC treatment.
Rajat Thawani, MD, shares key...
08/28/2025
Journal of Clinical Pathways
Blog
CPC+CBEx 2025 Abstracts: Business Models, Breakthrough Tools, and Data-Driven Decisions Driving the Future of Cancer Care
08/27/2025
The 2025 Clinical Pathways Congress + Cancer Care Business Exchange (CPC+CBEx), to be held September 5-6 in Boston, will confront these challenges head-on through 13 powerful abstracts that demonstrate what it takes to translate evidence into...
The 2025 Clinical Pathways Congress + Cancer Care Business Exchange (CPC+CBEx), to be held September 5-6 in Boston, will confront these challenges head-on through 13 powerful abstracts that demonstrate what it takes to translate evidence into...
The 2025 Clinical Pathways...
08/27/2025
Journal of Clinical Pathways
Wilfong Headshot
Videos
Driving Change: What the PCC Working Group Has Learned and What’s Next
08/20/2025
Lalan Wilfong, MD
The Predictable Cost of Care Working Group (the PCC) is a multi-organizational effort comprised of pharmaceutical and biotech manufacturers, pathway vendor organizations, community practices, IDNs, and payers. The purpose of the PCC is to...
The Predictable Cost of Care Working Group (the PCC) is a multi-organizational effort comprised of pharmaceutical and biotech manufacturers, pathway vendor organizations, community practices, IDNs, and payers. The purpose of the PCC is to...
The Predictable Cost of Care...
08/20/2025
Journal of Clinical Pathways
ONLINE EXCLUSIVES
Developing a National Pathway Framework for Prostate Cancer: Insights From Solaris Health
08/15/2025
Jason Hafron, MD
Jason Hafron, MD, discusses how Solaris Health developed and implemented standardized, National Comprehensive Cancer Network (NCCN)-based prostate cancer pathways across its national network to ensure consistent, high-quality care, streamline...
Jason Hafron, MD, discusses how Solaris Health developed and implemented standardized, National Comprehensive Cancer Network (NCCN)-based prostate cancer pathways across its national network to ensure consistent, high-quality care, streamline...
Jason Hafron, MD, discusses how...
08/15/2025
Journal of Clinical Pathways
Jennifer Woyach, MD
Interview
Overcoming Resistance to Targeted Therapies in CLL Through Personalized Treatment Approaches
08/13/2025
Jennifer Ann Woyach, MD
This expert interview explores how emerging resistance mechanisms to Bruton tyrosine kinase (BTK) and BCL2 inhibitors are reshaping personalized treatment strategies and diagnostic workflows in chronic lymphocytic leukemia (CLL).
This expert interview explores how emerging resistance mechanisms to Bruton tyrosine kinase (BTK) and BCL2 inhibitors are reshaping personalized treatment strategies and diagnostic workflows in chronic lymphocytic leukemia (CLL).
This expert interview explores...
08/13/2025
Journal of Clinical Pathways
Henschel
Videos
Driving Change: What the PCC Working Group Has Learned and What’s Next
08/13/2025
Rhonda Henschel, MBA
The Predictable Cost of Care Working Group (the PCC) is a multi-organizational effort comprised of pharmaceutical and biotech manufacturers, pathway vendor organizations, community practices, IDNs, and payers. The purpose of the PCC is to...
The Predictable Cost of Care Working Group (the PCC) is a multi-organizational effort comprised of pharmaceutical and biotech manufacturers, pathway vendor organizations, community practices, IDNs, and payers. The purpose of the PCC is to...
The Predictable Cost of Care...
08/13/2025
Journal of Clinical Pathways
Arrowsmith Headshot
Videos
Driving Change: What the PCC Working Group Has Learned and What’s Next
08/08/2025
Edward Arrowsmith, MD
The Predictable Cost of Care Working Group (the PCC) is a multi-organizational effort comprised of pharmaceutical and biotech manufacturers, pathway vendor organizations, community practices, IDNs, and payers. The purpose of the PCC is to...
The Predictable Cost of Care Working Group (the PCC) is a multi-organizational effort comprised of pharmaceutical and biotech manufacturers, pathway vendor organizations, community practices, IDNs, and payers. The purpose of the PCC is to...
The Predictable Cost of Care...
08/08/2025
Journal of Clinical Pathways

Newsfeed

Conference Coverage
Hospital Costs and Health Care Resource Utilization for Chimeric Antigen T-Cell Therapy and Stem Cell Transplant in Patients with Large B-Cell Lymphoma in the United States
12/12/2022
Katie Herman
At the 64th ASH Annual Meeting and Exposition, Gunjan L Shah, MD, described and compared hospital costs and health care resource utilization of chimeric antigen T-cell therapy and stem cell transplant for the procedure, preprocedure, and...
At the 64th ASH Annual Meeting and Exposition, Gunjan L Shah, MD, described and compared hospital costs and health care resource utilization of chimeric antigen T-cell therapy and stem cell transplant for the procedure, preprocedure, and...
At the 64th ASH Annual Meeting...
12/12/2022
Journal of Clinical Pathways
News
HCRU and End-of-Life Outcomes Among Patients Receiving CAR-T Therapy
08/05/2021
Findings from a recent study indicate that intervention may be needed to optimize health care delivery and end-of-life care in patients with hematologic malignancies receiving CAR-T therapy.
Findings from a recent study indicate that intervention may be needed to optimize health care delivery and end-of-life care in patients with hematologic malignancies receiving CAR-T therapy.
Findings from a recent study...
08/05/2021
Journal of Clinical Pathways
News
Real-World CAR-T Therapy Toxicity in Patients With DLBCL
11/11/2020
More studies exploring real-world experience and data are necessary and will help define and refine management of toxicities unique to CAR-T therapy.
More studies exploring real-world experience and data are necessary and will help define and refine management of toxicities unique to CAR-T therapy.
More studies exploring...
11/11/2020
Journal of Clinical Pathways
News
HHS Final Rule Expands Real-Time Prescription Access, Eases Prior Authorization Burdens
09/26/2025
Grace Taylor, MS, MA
A sweeping new US Department of Health and Human Services (HHS) rule taking effect October 1 will give doctors and patients real-time access to drug costs and prior authorization decisions.
A sweeping new US Department of Health and Human Services (HHS) rule taking effect October 1 will give doctors and patients real-time access to drug costs and prior authorization decisions.
A sweeping new US Department of...
09/26/2025
Journal of Clinical Pathways
News
NRF2 Inhibition Emerges as a Promising Strategy to Halt Esophageal Cancer Spread
08/13/2025
Lisa Kuhns, PhD, MD
Researchers have identified a promising new target to combat the deadly spread of esophageal squamous cell carcinoma (ESCC) by focusing on a master regulatory protein called NRF2, according to a study published in Cancers.
Researchers have identified a promising new target to combat the deadly spread of esophageal squamous cell carcinoma (ESCC) by focusing on a master regulatory protein called NRF2, according to a study published in Cancers.
Researchers have identified a...
08/13/2025
Journal of Clinical Pathways
News
Palliative Care Use Rose 24% in Medicare Cancer Decedents, but Disparities Persist
08/12/2025
Hannah Musick
Specialty palliative care use among Medicare decedents with poor-prognosis cancers grew significantly between 2018 and 2023. The change is driven by outpatient services, telehealth, and advanced practice clinicians—yet older adults,...
Specialty palliative care use among Medicare decedents with poor-prognosis cancers grew significantly between 2018 and 2023. The change is driven by outpatient services, telehealth, and advanced practice clinicians—yet older adults,...
Specialty palliative care use...
08/12/2025
Journal of Clinical Pathways
News
Perioperative Durvalumab-FLOT Regimen Demonstrates Superior Efficacy Over FLOT Alone
08/06/2025
Juliet Gallagher
A new phase 3 study published in the New England Journal of Medicine presents compelling evidence that perioperative durvalumab combined with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy significantly improves...
A new phase 3 study published in the New England Journal of Medicine presents compelling evidence that perioperative durvalumab combined with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy significantly improves...
A new phase 3 study published in...
08/06/2025
Journal of Clinical Pathways
News
Specialized Teams Improve Safety as Immunotherapy Use Surges in Cancer Care
07/30/2025
Lisa Kuhns, PhD, MD
As immunotherapy continues to transform cancer treatment, multidisciplinary teams are proving essential for managing the potentially severe toxicities that accompany these therapies, according to an article published in the American Society...
As immunotherapy continues to transform cancer treatment, multidisciplinary teams are proving essential for managing the potentially severe toxicities that accompany these therapies, according to an article published in the American Society...
As immunotherapy continues to...
07/30/2025
Journal of Clinical Pathways
News
NCCN Launches Interactive NCCN Guidelines Navigator to Advance Cancer Care Usability
07/11/2025
Grace Taylor, MS, MA
Discover how the National Comprehensive Cancer Network’s (NCCN) new digital Guidelines Navigator is transforming cancer care delivery with smarter, faster, and more accessible clinical guidelines.
Discover how the National Comprehensive Cancer Network’s (NCCN) new digital Guidelines Navigator is transforming cancer care delivery with smarter, faster, and more accessible clinical guidelines.
Discover how the National...
07/11/2025
Journal of Clinical Pathways
News
Study Finds Key Risk Factors for Gastric Cancer in US Patients With Chronic Gastritis
07/11/2025
Lisa Kuhns, PhD, MD
Adults under age 65 diagnosed with chronic atrophic gastritis (CAG) face a measurable risk of progressing to non-cardia gastric cancer (NCGC), with certain clinical and demographic factors significantly increasing that risk.
Adults under age 65 diagnosed with chronic atrophic gastritis (CAG) face a measurable risk of progressing to non-cardia gastric cancer (NCGC), with certain clinical and demographic factors significantly increasing that risk.
Adults under age 65 diagnosed...
07/11/2025
Journal of Clinical Pathways
News
Persistent Barriers in Gastric Cancer Care: GI Cancers Alliance Study
07/09/2025
Grace Taylor, MS, MA
A year-long study by the GI Cancers Alliance reveals critical gaps in gastric cancer care, highlighting persistent disparities in biomarker access, patient education, and mental health support.
A year-long study by the GI Cancers Alliance reveals critical gaps in gastric cancer care, highlighting persistent disparities in biomarker access, patient education, and mental health support.
A year-long study by the GI...
07/09/2025
Journal of Clinical Pathways
News
Nivolumab-Based Regimens Extend Survival in Advanced Gastroesophageal Cancer Based on Molecular Biomarkers
06/25/2025
Lisa Kuhns, PhD, MD
Nivolumab-based immunotherapy shows promise in extending survival for patients with advanced gastroesophageal adenocarcinoma, particularly in those with specific molecular and genomic profiles, according to study results published in Nature...
Nivolumab-based immunotherapy shows promise in extending survival for patients with advanced gastroesophageal adenocarcinoma, particularly in those with specific molecular and genomic profiles, according to study results published in Nature...
Nivolumab-based immunotherapy...
06/25/2025
Journal of Clinical Pathways
News
Study Shows Improved Outcomes in Older Adults With Mantle Cell Lymphoma Following Adoption of New Therapies
06/16/2025
Juliet Gallagher
New findings from a large, retrospective cohort study using SEER-Medicare data highlight improvements in survival outcomes over time among older adults with mantle cell lymphoma (MCL), likely associated with the adoption of novel therapeutic...
New findings from a large, retrospective cohort study using SEER-Medicare data highlight improvements in survival outcomes over time among older adults with mantle cell lymphoma (MCL), likely associated with the adoption of novel therapeutic...
New findings from a large,...
06/16/2025
Journal of Clinical Pathways

Interactive Features

Quiz
Uncovering the True Cost of Care
09/18/2025
Learn more about the Predictable Cost of Care (PCOC) model and its applications in value-based care.
Learn more about the Predictable Cost of Care (PCOC) model and its applications in value-based care.
Learn more about the Predictable...
09/18/2025
Journal of Clinical Pathways
Quiz
Understanding the NCCN Guidelines Navigator
08/27/2025
The National Comprehensive Cancer Network (NCCN) Guidelines Navigator is a new interactive digital platform that delivers evidence-based oncology recommendations and is currently available for all 88 NCCN guideline sets.
The National Comprehensive Cancer Network (NCCN) Guidelines Navigator is a new interactive digital platform that delivers evidence-based oncology recommendations and is currently available for all 88 NCCN guideline sets.
The National Comprehensive...
08/27/2025
Journal of Clinical Pathways
Quiz
Specialty Palliative Care Trends for Medicare Beneficiaries
08/12/2025
Between 2018 and 2023, which of the following trends was observed in the delivery of specialty palliative care (PC) among Medicare beneficiaries with poor-prognosis cancers?
Between 2018 and 2023, which of the following trends was observed in the delivery of specialty palliative care (PC) among Medicare beneficiaries with poor-prognosis cancers?
Between 2018 and 2023, which of...
08/12/2025
Journal of Clinical Pathways
Quiz
Understanding the Role of Clinical Pathways in Oncology Care
07/30/2025
Learn more about how clinical pathways are helping multidisciplinary teams standardize cancer care, reduce costs, and improve outcomes—and why aligning them with evidence-based guidelines is essential in today’s value-based healthcare...
Learn more about how clinical pathways are helping multidisciplinary teams standardize cancer care, reduce costs, and improve outcomes—and why aligning them with evidence-based guidelines is essential in today’s value-based healthcare...
Learn more about how clinical...
07/30/2025
Journal of Clinical Pathways
SPONSORED QUIZ BY SANOFI
Treatments in Multiple Myeloma
11/28/2022
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA...
11/28/2022
Journal of Clinical Pathways
Quiz
Quiz: Medicaid Insurance and Biomarker Testing in NSCLC
07/26/2022
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid...
07/26/2022
Journal of Clinical Pathways
Quiz
Quiz: Comparing the Cost of Regimens in Newly Diagnosed Multiple Myeloma
07/14/2022
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among...
07/14/2022
Journal of Clinical Pathways
Quiz
Quiz: Germline BRCA Testing in Ovarian Cancer
07/12/2022
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of...
07/12/2022
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of Margetuximab vs Trastuzumab for Breast Cancer
06/30/2022
True or False: Under a willingness-to-pay threshold of $100,000 per quality-adjusted life year, margetuximab plus chemotherapy is cost-effective compared to trastuzumab plus chemotherapy for patients with ERBB2–positive, advanced breast...
True or False: Under a willingness-to-pay threshold of $100,000 per quality-adjusted life year, margetuximab plus chemotherapy is cost-effective compared to trastuzumab plus chemotherapy for patients with ERBB2–positive, advanced breast...
True or False: Under a...
06/30/2022
Journal of Clinical Pathways
Quiz
Quiz: Real-World Treatment Patterns in Mantle Cell Lymphoma
06/28/2022
True or False: Bendamustine and rituximab was the most used frontline regimen for the treatment of MCL, while BTK inhibitors were the most used agents in later lines of therapy.
True or False: Bendamustine and rituximab was the most used frontline regimen for the treatment of MCL, while BTK inhibitors were the most used agents in later lines of therapy.
True or False: Bendamustine and...
06/28/2022
Journal of Clinical Pathways
JCP July-Aug Cover 2025

Current Issue

August 2025
Volume 11
Issue 4
Current Issue
Issue Archive

Special Reports

Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
08/15/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
08/15/2025
Journal of Clinical Pathways
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
08/15/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
08/15/2025
Journal of Clinical Pathways
Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
06/12/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
06/12/2025
Journal of Clinical Pathways
Page 1
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
02/19/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
02/19/2025
Journal of Clinical Pathways
JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Robin T. Zon, MD, FACP, FASCO; Gordon Kuntz; Winston Wong, PharmD
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

Subscribe

Journal of Clinical Pathways Newsletter

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use